Structural and Functional Evaluation of Coronary Arteries Treated With ABSORB Bioresorbable Vascular Scaffold at 5-Year Follow-Up
Introduction
The everolimus-eluting bioresorbable vascular scaffold (Absorb-BVS; Abbott Vascular, California) was the backbone of poly-L-lactic acid coated with poly-DL-lactic polymer, which eluted everolimus.1 Although good early outcomes were initially described,2,3 more recent data have questioned its safety, with higher rates of short-term scaffold thrombosis, myocardial infarction, and target-vessel revascularization.4, 5, 6, 7 Whether these findings relate to the device per se or to suboptimal implantation technique remains contentious, but still lead to the ABSORB-BVS market withdrawal.8,9 However, many questions remain unresolved regarding the longer-term performance of the ABSORB-BVS implanted in real-world patients. Although the resorption capacity was demonstrated in some ABSORB-BVS recipients, less is known of whether this healing response correlates with functional restoration of the vessel (theoretical advantage of BVS).2,3,10, 11, 12, 13, 14, 15 Therefore, we characterized coronary structural changes and epicardial vasomotor responses in patients with ABSORB-BVS at 5-year follow-up, using quantitative coronary angiography (QCA) and optical coherence tomography (OCT).
Section snippets
Methods
Patients were selected from a multicenter registry of consecutive ABSORB-BVS recipients who were ≥3 years postimplant, who agreed to undergo a follow-up research-protocol intracoronary imaging and vasomotor testing protocol. Patients with a new percutaneous coronary intervention (PCI) within the culprit artery/segment or patients with a contraindication for intracoronary acetylcholine (ACh) provocation testing were excluded from enrollment. In total, 125 patients were enrolled to undergo OCT
Results
Baseline clinical characteristics and procedural data of the included patients are shown in Table 1. The follow-up was 60.5 ± 4.6 months. A total of 5 patients underwent new PCI, 3 of whom were performed on scaffolded arteries. A late thrombosis of the device and a restenosis at 6 months of follow-up were described. Regarding control coronary angiography, new coronary lesions (stenosis >50%) were found in 5 patients, 3 of whom underwent ad hoc PCI. Both patients who underwent PCI and those with
Discussion
Although Absorb-BVS market withdrawal was undertaken due to a higher incidence of scaffold thrombosis, myocardial infarction, and target-vessel revascularization,4, 5, 6, 7 several alternative BVS technologies cautiously remain in the spotlight. Questions remain, however, regarding long-term structural and functional changes of coronary segments after complete scaffold resorption. In fact, whether coronary vasomotion recovers in vivo, remains a controversial issue since few studies (if any)
Acknowledgment
The authors would like to thank Roman Poliszczuk of the angio/IVUS Core Laboratory of the Cleveland Clinic Coordinating Center for Clinical Research for his contribution toward imaging analysis.
Disclosures
The authors have no conflicts of interest to declare.
References (24)
- et al.
A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods
Lancet
(2009) - et al.
2-year outcomes with the Absorb bioresorbable scaffold for treatment of coronary artery disease: a systematic review and meta-analysis of seven randomised trials with an individual patient data substudy
Lancet
(2017) - et al.
Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial
Lancet
(2016) - et al.
Outcomes with bioabsorbable vascular scaffolds versus everolimus eluting stents: insights from randomized trials
Int J Cardiol
(2016) - et al.
1-year outcomes with the Absorb bioresorbable scaffold in patients with coronary artery disease: a patient-level, pooled meta-analysis
Lancet
(2016) - et al.
Long-term coronary functional assessment of the infarct-related artery treated With everolimus-eluting bioresorbable scaffolds or everolimus-eluting metallic stents: insights of the TROFI II trial
JACC Cardiovasc Interv
(2018) - et al.
Functional and structural coronary recovery at the 5-year follow-up after bioresorbable vascular scaffold implantation. An optical coherence tomography analysis
Rev Esp Cardiol (Engl Ed)
(2019) - et al.
OCT assessment of the long-term vascular healing response 5 years after everolimus-eluting bioresorbable vascular scaffold
J Am Coll Cardiol
(2014) - et al.
Arterial remodeling after bioresorbable scaffolds and metallic stents
J Am Coll Cardiol
(2017) - et al.
Long-term intracoronary structural and vasomotor assessment of the ABSORB bioresorbable vascular scaffold
Am J Cardiol
(2022)
International Working Group for Intravascular Optical Coherence, Tomography. Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies: a report from the International Working Group for Intravascular Optical Coherence Tomography Standardization and Validation
J Am Coll Cardiol
Report of an ESC-EAPCI Task Force on the evaluation and use of bioresorbable scaffolds for percutaneous coronary intervention: executive summary
EuroIntervention
Cited by (0)
CIBERCV Valladolid received a nonconditional grant from Abbott Vascular (Spain) for REPARA and REPARA-QALY studies.